JP7592743B2 - Ｌｎｐ０２３の結晶形態 - Google Patents

Ｌｎｐ０２３の結晶形態 Download PDF

Info

Publication number
JP7592743B2
JP7592743B2 JP2022557633A JP2022557633A JP7592743B2 JP 7592743 B2 JP7592743 B2 JP 7592743B2 JP 2022557633 A JP2022557633 A JP 2022557633A JP 2022557633 A JP2022557633 A JP 2022557633A JP 7592743 B2 JP7592743 B2 JP 7592743B2
Authority
JP
Japan
Prior art keywords
methyl
lnp023
hydrochloride
indol
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022557633A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518552A (ja
Inventor
ジア，ジチェン
ルステンベルガー，フィリップ
メイヤー，マリエ
モラット，マッシモ
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2023518552A publication Critical patent/JP2023518552A/ja
Priority to JP2024103249A priority Critical patent/JP7789850B2/ja
Application granted granted Critical
Publication of JP7592743B2 publication Critical patent/JP7592743B2/ja
Priority to JP2025244399A priority patent/JP2026048795A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2022557633A 2020-05-18 2021-05-17 Ｌｎｐ０２３の結晶形態 Active JP7592743B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024103249A JP7789850B2 (ja) 2020-05-18 2024-06-26 Ｌｎｐ０２３の結晶形態
JP2025244399A JP2026048795A (ja) 2020-05-18 2025-12-10 Ｌｎｐ０２３の結晶形態

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063026637P 2020-05-18 2020-05-18
US63/026,637 2020-05-18
US202063052699P 2020-07-16 2020-07-16
US63/052,699 2020-07-16
PCT/IB2021/054225 WO2021234544A1 (en) 2020-05-18 2021-05-17 Crystalline form of lnp023

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024103249A Division JP7789850B2 (ja) 2020-05-18 2024-06-26 Ｌｎｐ０２３の結晶形態

Publications (2)

Publication Number Publication Date
JP2023518552A JP2023518552A (ja) 2023-05-02
JP7592743B2 true JP7592743B2 (ja) 2024-12-02

Family

ID=76076387

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022557633A Active JP7592743B2 (ja) 2020-05-18 2021-05-17 Ｌｎｐ０２３の結晶形態
JP2024103249A Active JP7789850B2 (ja) 2020-05-18 2024-06-26 Ｌｎｐ０２３の結晶形態
JP2025244399A Pending JP2026048795A (ja) 2020-05-18 2025-12-10 Ｌｎｐ０２３の結晶形態

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024103249A Active JP7789850B2 (ja) 2020-05-18 2024-06-26 Ｌｎｐ０２３の結晶形態
JP2025244399A Pending JP2026048795A (ja) 2020-05-18 2025-12-10 Ｌｎｐ０２３の結晶形態

Country Status (10)

Country Link
US (3) US11603363B2 (https=)
EP (1) EP4153580A1 (https=)
JP (3) JP7592743B2 (https=)
KR (2) KR20230009478A (https=)
CN (4) CN120168469A (https=)
AU (2) AU2021276912B2 (https=)
CA (1) CA3180829A1 (https=)
IL (1) IL297975A (https=)
TW (2) TW202504893A (https=)
WO (1) WO2021234544A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024517234A (ja) * 2021-05-07 2024-04-19 ノバルティス アーゲー 非典型溶血性尿毒症症候群の処置のためのイプタコパン

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3675854T1 (sl) 2017-08-31 2025-05-30 Novartis Ag Derivati piperidinil-indola za uporabo v zdravljenju glomerulopatije c3
TW202504893A (zh) * 2020-05-18 2025-02-01 瑞士商諾華公司 Lnp023之結晶形式
US11951101B2 (en) 2020-07-16 2024-04-09 Novartis Ag Methods of using factor B inhibitors
WO2022143940A1 (zh) * 2020-12-30 2022-07-07 南京明德新药研发有限公司 一系列哌啶取代的苯酸类化合物及其应用
WO2022264101A1 (en) 2021-06-18 2022-12-22 Novartis Ag Method of treating an autoimmune hematological disorder
CA3248808A1 (en) 2022-03-04 2023-09-07 Novartis Ag USE OF IPTACOPAN FOR THE TREATMENT OF LUPUS NEPHROPATHY
JP7849520B2 (ja) * 2022-06-30 2026-04-21 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 含窒素架橋複素環誘導体の薬学的に許容される塩、結晶形及びその調製方法
EP4669321A1 (en) 2023-02-23 2025-12-31 Novartis AG METHODS OF USING FACTOR B INHIBITORS
CN121712505A (zh) 2023-08-25 2026-03-20 诺华股份有限公司 使用因子b抑制剂的方法
WO2025148628A1 (zh) * 2024-01-10 2025-07-17 河北以岭医药研究院有限公司 哌啶基吲哚衍生物及其制备方法和应用
WO2025172910A1 (en) 2024-02-16 2025-08-21 Novartis Ag Factor b inhibitors for treatment of anca-associated vasculitis
WO2026003809A1 (en) * 2024-06-29 2026-01-02 Assia Chemical Industries Ltd. Solid state forms of iptacopan hydrochloride

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013527239A (ja) 2010-06-01 2013-06-27 プラス・ケミカルス・エスアー イクサベピロンの固体形
JP2016526576A (ja) 2013-07-15 2016-09-05 ノバルティス アーゲー ピペリジニル−インドール誘導体および補体因子ｂ阻害剤としてのその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
MX2018007392A (es) 2015-12-23 2018-08-15 Greenovation Biotech Gmbh Polipeptidos para inhibir la activacion del complemento.
SI3675854T1 (sl) 2017-08-31 2025-05-30 Novartis Ag Derivati piperidinil-indola za uporabo v zdravljenju glomerulopatije c3
TW202504893A (zh) * 2020-05-18 2025-02-01 瑞士商諾華公司 Lnp023之結晶形式

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013527239A (ja) 2010-06-01 2013-06-27 プラス・ケミカルス・エスアー イクサベピロンの固体形
JP2016526576A (ja) 2013-07-15 2016-09-05 ノバルティス アーゲー ピペリジニル−インドール誘導体および補体因子ｂ阻害剤としてのその使用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Ｊ．Ｍｅｄ．Ｃｈｅｍ．，２０２０年２月，６３（１１），ｐ．５６９７－５７２２
岸田宗己，エカベトナリウム水和物の晶析における粒径と形状の同時制御およびそのメカニズム，大阪市立大学博士（工学）論文，甲第３７８３号，２０１９，ｈｔｔｐｓ：／／ｗｗｗ．ｉ－ｒｅｐｏｓｉｔｏｒｙ．ｎｅｔ／ｃｏｎｔｅｎｔｓ／ｏｓａｋａｃｕ／ｋｉｙｏ／１１１ＴＤＡ３７８３．ｐｄｆ
平山令明編，有機化合物結晶作製ハンドブック－原理とノウハウ－，丸善株式会社，２００８年７月２５日，ｐ．５７－７９
有機合成化学協会誌，２００７，６５（９），ｐ．９０７－９１３

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024517234A (ja) * 2021-05-07 2024-04-19 ノバルティス アーゲー 非典型溶血性尿毒症症候群の処置のためのイプタコパン

Also Published As

Publication number Publication date
JP2024150466A (ja) 2024-10-23
JP2026048795A (ja) 2026-03-17
AU2021276912B2 (en) 2023-12-14
CN120168469A (zh) 2025-06-20
WO2021234544A1 (en) 2021-11-25
AU2024201640B2 (en) 2025-10-09
KR20250048392A (ko) 2025-04-08
IL297975A (en) 2023-01-01
KR20230009478A (ko) 2023-01-17
CN120208923A (zh) 2025-06-27
TW202204335A (zh) 2022-02-01
TWI858258B (zh) 2024-10-11
US20230265067A1 (en) 2023-08-24
US11603363B2 (en) 2023-03-14
JP7789850B2 (ja) 2025-12-22
AU2021276912A1 (en) 2022-11-24
TW202504893A (zh) 2025-02-01
EP4153580A1 (en) 2023-03-29
CA3180829A1 (en) 2021-11-25
AU2024201640A1 (en) 2024-04-04
CN115667240B (zh) 2025-04-22
CN120172955A (zh) 2025-06-20
JP2023518552A (ja) 2023-05-02
CN115667240A (zh) 2023-01-31
US20250270186A1 (en) 2025-08-28
US12384758B2 (en) 2025-08-12
US20210371394A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
JP7592743B2 (ja) Ｌｎｐ０２３の結晶形態
JP2022531969A (ja) 癌を治療するためのＲａｆ阻害剤としてのＮ－（３－（２－（２－ヒドロキシエトキシ）－６－モルホリノピリジン－４－イル）－４－メチルフェニル）－２－（トリフルオロメチル）イソニコチンアミドの新規な結晶形態
WO2020228746A1 (en) Crystalline forms of n- (5- (5- ( (1r, 2s) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide
JP2024523518A (ja) ソトラシブの結晶形態
US12590095B2 (en) Crystalline forms of an orally available, selective kit and PDGFR kinase inhibitor
EP3887356B1 (en) Multi-component crystals of an orally available hif prolyl hydroxylase inhibitor
RU2818684C1 (ru) Кристаллическая форма lnp023
WO2021259732A1 (en) Multi-component compounds comprising zanubrutinib and a benzoic acid derivative
JP6594325B2 (ja) 臭化チオトロピウムとラクトースの結晶形態
US20240327379A1 (en) Mandelate form of 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231215

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240626

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240703

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241002

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241120

R150 Certificate of patent or registration of utility model

Ref document number: 7592743

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150